FindTrial
Sign In

ADI-001

DRUG4 trials

Sponsors

Adicet Therapeutics

Conditions

ANCA-Associated Vasculitis (AAV)Autoimmune DiseasesDiffuse Large B Cell LymphomaIdiopathic Inflammatory MyopathiesLupus NephritisLymphoma, FollicularLymphoma, Mantle-CellLymphoma, Non-Hodgkin

Phase 1

A Phase 1 Study of ADI-001 in B Cell Malignancies
TerminatedNCT04735471
Adicet TherapeuticsDiffuse Large B Cell Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell +3
Start: 2021-03-04End: 2025-02-03Updated: 2025-06-18
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
Enrolling by invitationNCT06375993
Adicet TherapeuticsANCA-Associated Vasculitis (AAV), Autoimmune Diseases, Idiopathic Inflammatory Myopathies +4
Start: 2024-11-10End: 2027-12-01Target: 180Updated: 2026-03-19
A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
RecruitingNCT07100873
Adicet TherapeuticsRheumatoid Arthritis (RA)
Start: 2025-10-10End: 2028-03-30Target: 25Updated: 2025-12-08

Unknown Phase

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
Active, not recruitingNCT04911478
Adicet TherapeuticsDiffuse Large B Cell Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell +3
Start: 2022-02-14End: 2039-08-01Target: 50Updated: 2026-04-09

Related Papers

Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Blood2023-11-0210 citations
684 Assay development and quantitative detection of ADI-001, a CD20-targeted γδ1 CAR T therapy, using AlloCell, a universal assay for monitoring of off-the-shelf allogeneic cell therapies
Regular and Young Investigator Award Abstracts2023-10-31
A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies.
Journal of Clinical Oncology2022-06-0140 citations
Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models
Clinical & Translational Immunology2022-01-0198 citations
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2
Blood2021-11-057 citations